HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.

AuthorsS R Quist, G Fierlbeck, R A Seaton, J Loeffler, R L Chaves
JournalInternational journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 39 Issue 1 Pg. 90-1 (Jan 2012) ISSN: 1872-7913 [Electronic] Netherlands
PMID21982144 (Publication Type: Clinical Trial, Phase III, Comparative Study, Letter, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Glycopeptides
  • Teicoplanin
  • Vancomycin
  • Daptomycin
Topics
  • Aged
  • Anti-Bacterial Agents (therapeutic use)
  • Daptomycin (adverse effects, therapeutic use)
  • Glycopeptides (adverse effects, therapeutic use)
  • Humans
  • Methicillin-Resistant Staphylococcus aureus (drug effects)
  • Middle Aged
  • Soft Tissue Infections (drug therapy, microbiology)
  • Staphylococcal Skin Infections (drug therapy, microbiology)
  • Staphylococcus aureus (drug effects)
  • Teicoplanin (therapeutic use)
  • Vancomycin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: